COLUMBIA, Md. (
(OSIR - Get Report)
CEO Randy Mills, speaking to investors on his company's first-quarter conference call Tuesday morning about Prochymal, a stem cell therapy for graft-versus-host disease:
We have made Prochymal by far -- by far -- the most widely used stem cell drug in the world. So, we regularly and constantly treat patients now on four different continents and are literally treating a patient with Prochymal anywhere around the world at any given time of the day.
Prochymal is the most widely used stem cell drug in the world? Really?
Mills has a different definition of "widely used" than most investors.
Prochymal sales since the stem cell drug was approved in Canada in May 2012 and New Zealand in June 2012: $0.
Reimbursement process in Canada: Incomplete.
Update on Prochymal confirmatory trial, which is
required as part of Canadian approval
Status of long-delayed plans to submit Prochymal for U.S. approval: On permanent hold.
-- Reported by Adam Feuerstein in Boston.